Smoking, DNA Methylation, and Breast Cancer: A Mendelian Randomization Study
BackgroundSmoking was strongly associated with breast cancer in previous studies. Whether smoking promotes breast cancer through DNA methylation remains unknown.MethodsTwo-sample Mendelian randomization (MR) analyses were conducted to assess the causal effect of smoking-related DNA methylation on br...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.745918/full |
id |
doaj-f50140d71e8e48a087eee32a703d1f90 |
---|---|
record_format |
Article |
spelling |
doaj-f50140d71e8e48a087eee32a703d1f902021-09-28T12:10:24ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-09-011110.3389/fonc.2021.745918745918Smoking, DNA Methylation, and Breast Cancer: A Mendelian Randomization StudyHaibo Tang0Desong Yang1Chaofei Han2Ping Mu3Department of Metabolic and Bariatric Surgery, The Third Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Thoracic Surgery II, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, ChinaDepartment of Burn and Plastic Surgery, The Third Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Physiology, Shenyang Medical College, Shenyang, ChinaBackgroundSmoking was strongly associated with breast cancer in previous studies. Whether smoking promotes breast cancer through DNA methylation remains unknown.MethodsTwo-sample Mendelian randomization (MR) analyses were conducted to assess the causal effect of smoking-related DNA methylation on breast cancer risk. We used 436 smoking-related CpG sites extracted from 846 middle-aged women in the ARIES project as exposure data. We collected summary data of breast cancer from one of the largest meta-analyses, including 69,501 cases for ER+ breast cancer and 21,468 cases for ER− breast cancer. A total of 485 single-nucleotide polymorphisms (SNPs) were selected as instrumental variables (IVs) for smoking-related DNA methylation. We further performed an MR Steiger test to estimate the likely direction of causal estimate between DNA methylation and breast cancer. We also conducted colocalization analysis to evaluate whether smoking-related CpG sites shared a common genetic causal SNP with breast cancer in a given region.ResultsWe established four significant associations after multiple testing correction: the CpG sites of cg2583948 [OR = 0.94, 95% CI (0.91–0.97)], cg0760265 [OR = 1.07, 95% CI (1.03–1.11)], cg0420946 [OR = 0.95, 95% CI (0.93–0.98)], and cg2037583 [OR =1.09, 95% CI (1.04–1.15)] were associated with the risk of ER+ breast cancer. All the four smoking-related CpG sites had a larger variance than that in ER+ breast cancer (all p < 1.83 × 10−11) in the MR Steiger test. Further colocalization analysis showed that there was strong evidence (based on PPH4 > 0.8) supporting a common genetic causal SNP between the CpG site of cg2583948 [with IMP3 expression (PPH4 = 0.958)] and ER+ breast cancer. There were no causal associations between smoking-related DNA methylation and ER− breast cancer.ConclusionsThese findings highlight potential targets for the prevention of ER+ breast cancer. Tissue-specific epigenetic data are required to confirm these results.https://www.frontiersin.org/articles/10.3389/fonc.2021.745918/fullMendelian randomization (MR)smokingDNA methylationbreast cancercausal inference |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Haibo Tang Desong Yang Chaofei Han Ping Mu |
spellingShingle |
Haibo Tang Desong Yang Chaofei Han Ping Mu Smoking, DNA Methylation, and Breast Cancer: A Mendelian Randomization Study Frontiers in Oncology Mendelian randomization (MR) smoking DNA methylation breast cancer causal inference |
author_facet |
Haibo Tang Desong Yang Chaofei Han Ping Mu |
author_sort |
Haibo Tang |
title |
Smoking, DNA Methylation, and Breast Cancer: A Mendelian Randomization Study |
title_short |
Smoking, DNA Methylation, and Breast Cancer: A Mendelian Randomization Study |
title_full |
Smoking, DNA Methylation, and Breast Cancer: A Mendelian Randomization Study |
title_fullStr |
Smoking, DNA Methylation, and Breast Cancer: A Mendelian Randomization Study |
title_full_unstemmed |
Smoking, DNA Methylation, and Breast Cancer: A Mendelian Randomization Study |
title_sort |
smoking, dna methylation, and breast cancer: a mendelian randomization study |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-09-01 |
description |
BackgroundSmoking was strongly associated with breast cancer in previous studies. Whether smoking promotes breast cancer through DNA methylation remains unknown.MethodsTwo-sample Mendelian randomization (MR) analyses were conducted to assess the causal effect of smoking-related DNA methylation on breast cancer risk. We used 436 smoking-related CpG sites extracted from 846 middle-aged women in the ARIES project as exposure data. We collected summary data of breast cancer from one of the largest meta-analyses, including 69,501 cases for ER+ breast cancer and 21,468 cases for ER− breast cancer. A total of 485 single-nucleotide polymorphisms (SNPs) were selected as instrumental variables (IVs) for smoking-related DNA methylation. We further performed an MR Steiger test to estimate the likely direction of causal estimate between DNA methylation and breast cancer. We also conducted colocalization analysis to evaluate whether smoking-related CpG sites shared a common genetic causal SNP with breast cancer in a given region.ResultsWe established four significant associations after multiple testing correction: the CpG sites of cg2583948 [OR = 0.94, 95% CI (0.91–0.97)], cg0760265 [OR = 1.07, 95% CI (1.03–1.11)], cg0420946 [OR = 0.95, 95% CI (0.93–0.98)], and cg2037583 [OR =1.09, 95% CI (1.04–1.15)] were associated with the risk of ER+ breast cancer. All the four smoking-related CpG sites had a larger variance than that in ER+ breast cancer (all p < 1.83 × 10−11) in the MR Steiger test. Further colocalization analysis showed that there was strong evidence (based on PPH4 > 0.8) supporting a common genetic causal SNP between the CpG site of cg2583948 [with IMP3 expression (PPH4 = 0.958)] and ER+ breast cancer. There were no causal associations between smoking-related DNA methylation and ER− breast cancer.ConclusionsThese findings highlight potential targets for the prevention of ER+ breast cancer. Tissue-specific epigenetic data are required to confirm these results. |
topic |
Mendelian randomization (MR) smoking DNA methylation breast cancer causal inference |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.745918/full |
work_keys_str_mv |
AT haibotang smokingdnamethylationandbreastcanceramendelianrandomizationstudy AT desongyang smokingdnamethylationandbreastcanceramendelianrandomizationstudy AT chaofeihan smokingdnamethylationandbreastcanceramendelianrandomizationstudy AT pingmu smokingdnamethylationandbreastcanceramendelianrandomizationstudy |
_version_ |
1716866215836647424 |